Commercial Supply of Actinium-225

Currently clinical-quality Ac-225 is obtained from Th-229 (daughter product of U-233) generators. U-233 reserves are from the legacy nuclear activities.

TRIUMF and Canadian Nuclear Laboratories (CNL), will advance and develop processes for the production of clinical-grade actinium-225 (Ac-225), having a key role in Targeted Radionuclide Therapy (TRT) and the promise to deliver cell-destroying radiation directly to cancer sites. The development of radiopharmaceuticals based on Ac-225 continues to grow, but the research and trials are being restricted because the global supply of this radioisotope is only enough for about approximately 2,000 patient doses a per year.